Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,594.50
Ask: 1,595.50
Change: -19.00 (-1.17%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TREASURIES-Yields lower, curve flatter ahead of Fed

Fri, 11th Dec 2020 21:23

(New throughout)
By Kate Duguid
NEW YORK, Dec 11 (Reuters) - A risk-off move drove Treasury
yields down across maturities on Friday, with the two-year yield
falling to a four-month low, furthering speculation that the
Federal Reserve may announce adjustments to its Treasury
purchases at next week's meeting.
The fall in yields was partly attributable to reports that
congressional wrangling over a spending package and coronavirus
aid could drag on through Christmas. Also pulling yields lower
was news that European pharmaceutical companies Sanofi SA
and GlaxoSmithKline Plc would delay the launch
of their COVID-19 vaccine until late next year, a setback in the
global fight against the pandemic.
Those macroeconomic drivers explain the fall in the
benchmark 10-year yield and the 30-year bond yield
to their lowest since Dec. 1. In afternoon trade,
both had pulled back from those lows, with the 10-year last down
1.5 basis points at 0.892% and the 30-year down 1.4 basis points
at 1.622%.
The move in the two-year yield to its lowest
since Aug. 7, however, was surprising, as the yield has been
roughly anchored since the Fed moved interest rates to zero at
the beginning of the pandemic. It was last down 2 basis points
at 0.119%.
Analysts argued the two-year move was likely not purely the
result of macroeconomic drivers. Yields on Treasury bills - debt
with a maturity of one year or less - are all less than 10 basis
points away from 0%, according to Tradeweb data.
"The idea that bills could potentially go to zero is taking
twos, threes and fives along with it," said Justin Lederer,
Treasury analyst and trader at Cantor Fitzgerald.
Since the lows hit in March, the 10-year yield has risen
more than 60 basis points, and the 30-year has risen nearly 100.
The two-year yield, by comparison, was just a basis point and a
half higher than the all-time low it hit in May.
Both long rates have increased enough in the past several
months that some analysts believe the Fed will purchase more
longer-dated debt to cap yields and keep borrowing costs low.
Since March the Fed has bought more than $2 trillion worth of
Treasury debt, most of it in shorter-dated notes.
If the Fed were to lengthen the average maturity of its
Treasury holdings - by purchasing the same amount but buying
more longer-dated debt and less shorter-dated debt - it could
also have the effect of bolstering Treasury bills and
shorter-dated notes away from zero.
"I can see the Fed trying to do something to alleviate that.
They definitely don't want bills trading negative, or repo
trading negative," said Lederer.

December 11 Friday 4:14PM New York / 2114 GMT
Price Current Net
Yield % Change
(bps)
Three-month bills 0.0725 0.0735 -0.006
Six-month bills 0.0825 0.0837 0.000
Two-year note 100-3/256 0.119 -0.020
Three-year note 99-216/256 0.1772 -0.019
Five-year note 100-16/256 0.3623 -0.021
Seven-year note 100 0.625 -0.021
10-year note 99-212/256 0.8931 -0.015
20-year bond 99-76/256 1.4156 -0.016
30-year bond 100-12/256 1.623 -0.013

DOLLAR SWAP SPREADS
Last (bps) Net
Change
(bps)
U.S. 2-year dollar swap 7.50 0.25
spread
U.S. 3-year dollar swap 6.00 0.00
spread
U.S. 5-year dollar swap 5.50 0.00
spread
U.S. 10-year dollar swap -1.00 -0.50
spread
U.S. 30-year dollar swap -29.00 -1.00
spread


(Reporting by Kate Duguid; Editing by Ken Ferris and Jonathan
Oatis)

More News
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.